Shots:
- Biocon Biologics secured full global rights to Hulio (Adalimumab), a biosimilar of adalimumab, from Fujifilm Kyowa Kirin Biologics
- As per the agreement, Biocon Biologics will take full responsibility for manufacturing, commercialization, and further development, while FKB will support development, offset certain development costs, and receive technology license fees and royalties for a specified tenure
- Biocon Biologics gained adalimumab biosimilar rights in 2022 through the Viatris biosimilars business acquisition
Ref: Biocon Biologics | Image: Biocon Biologics and Kyowa Kirin | Press Release
Related News: Viatris Enters Agreement to Monetize Equity Stake in Biocon Biologics for ~$815M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
